Osteonecrosis of the Jawbones in 2 Osteoporosis Patients Treated With Nitrogen-Containing Bisphosphonates: Osteonecrosis Reduction Replacing NBP With Non-NBP (Etidronate) and Rationale

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 4, 2010, Pages 889-897

  Yamaguchi, Kouji ^a   Oizumi, Takefumi ^a   Funayama, Hiromi ^b   Kawamura, Hiroshi ^a   Sugawara, Shunji ^a   Endo, Yasuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TSURUMI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMLODIN BESILATE; ANTIHYPERTENSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CEFCAPENE PIVOXIL; CLODRONIC ACID; ETIDRONIC ACID; LOXOPROFEN; MELOXICAM; RISEDRONIC ACID; TECHNETIUM 99M; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE SCINTISCANNING; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; JAW OSTEONECROSIS; MALE; MANDIBLE; OSTEOMYELITIS; OSTEOPOROSIS; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BINDING, COMPETITIVE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MANDIBULAR DISEASES; NITROGEN; OSTEOMYELITIS; OSTEONECROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RADIOPHARMACEUTICALS; TECHNETIUM COMPOUNDS; TOOTH EXTRACTION;

EID: 77949609132     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.04.048     Document Type: Article

References (47)

1. Geddes A.D., D'Souza S.M., Ebentino F.H., et al. Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heershe N.M., and Kanis J.K. (Eds). Bone and Mineral Research/8 (1994), Elsevier Science BV, Amsterdam 265-306
2. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961
3. Roelofs A.J., Thompson K., Gordon S., et al. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 12 suppl (2006) 6222s
4. Ruggiero S., Mebrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
5. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1767
6. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753
7. Pazianas M., Miller P., Blimentals W.A., et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics. Clin Ther 29 (2007) 1548
8. Shimahara M., Ariyoshi Y., Imai Y., et al. A survey of bisphosphonate-related osteomyelitis/osteonecrosis of the jaw. Jap J Oral Surg 53 (2007) 16 (Japanese, abstract in English)
9. Novartis home page (July 2006). http://www.novartis.co.jp/product/zom/te/te_arezom0607.html Accessed July 28, 2006
10. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24 (2006) 945
11. Funayama H., Ohsako M., Monma Y., et al. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. Calcif Tissue Int 76 (2005) 448
12. Endo Y., Nakamura N., Kikuchi T., et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 52 (1993) 248
13. Endo Y., Shibazaki M., Nakamura M., et al. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol 126 (1999) 903
14. Sugawara S., Shibazaki M., Takada H., et al. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice. Br J Pharmacol 125 (1998) 735
15. Funayama H., Mayanagi H., Takada H., et al. Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate. Arch Oral Biol 45 (2000) 787
16. Yamaguchi K., Motegi K., Iwakura Y., et al. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 130 (2000) 1646
17. Deng X., Yu Z., Funayama H., et al. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immunostimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol 213 (2006) 64
18. Oizumi T., Yamaguchi K., Funayama F., et al. Necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their inhibition by clodronate (a non-NBP) in mice: Potential for utilization of clodronate as a combination drug with an NBP. Basic Clin Pharmacol Toxicol 104 (2008) 384
19. Glorieux F.H., Bishop N.J., Plotkin H., et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339 (1998) 947
20. Devogelaer J.P., Malghem J., Maldague B., et al. Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16 (1987) 360
21. Monma Y., Funayama H., Mayanagi H., et al. Effects of weekly administrations of alendronate + clodronate on young mouse tibia: Localized action at the proximal growth plate. Calcif Tissue Int 74 (2004) 115
22. Yu Z., Funayama H., Deng X., et al. Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model. Basic Clin Pharmacol Toxicol 97 (2005) 222
23. Nakamura M., Ando T., Abe M., et al. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 119 (1996) 205
24. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
25. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508
26. Sato M., Grasser W., Endo N., et al. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095
27. Deng X., Yu Z., Funayama H., et al. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages, and T-cells. Int Immunopharmacol 7 (2007) 152
28. Mönkkönen J., Koponen H.-M., and Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 65 (1989) 294
29. Miyagawa F., Tanaka Y., Yamashita S., et al. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen. J Immunol 166 (2001) 5508
30. Gober H.-J., Kistowska M., Angman L., et al. Human T-cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197 (2003) 163
31. Thompson K., and Rogers M.J. Statins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitro. J Bone Miner Res 19 (2004) 278
32. Mariani S., Muraro M., Panteleoni F., et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19 (2005) 664
33. Kunzmann V., Bauer E., Feurle J., et al. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96 (2000) 384
34. Bürk M.R., Carena I., Donda A., et al. Functional inactivation in the whole population of human Vγ9/Vδ2 T lymphocytes induced by a nonpeptidic antagonist. J Exp Med 185 (1997) 91
35. Mestas J., and Hughes C.C.W. Of mice and not men: Differences between mouse and human immunology. J Immunol 172 (2004) 2731
36. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Invest Dermatol 126 (2006) 25
37. Adami S., Bhalla A.K., Dorizzi R., et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 41 (1987) 326
38. Mandey S.H.L., Kuijk L.M., Frenkel J., et al. A role for geranylgeranylation in interleukin-1 secretion. Arthritis Rheumat 54 (2006) 3690
39. Newton C.J., Ran G., Xie Y.X., et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 174 (2002) 7
40. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 320 (2004) 165
41. Watt I., and Hill P. Effects of acute administration of ethane hydroxydiphosphonate (EHDP) on skeletal scintigraphy with technetium-99m methylene diphosphonic acid (Tc-MDP) in the rat. Br J Radiol 54 (1981) 592
42. Krasnow A.Z., Collier B.D., Isitman A.T., et al. False-negative bone imaging due to etidronate therapy. Clin Nucl Med 13 (1988) 264
43. Sandler E.D., Parisi M.T., and Hattner R.S. Duration of etidronate effect demonstrated by serial bone scintigraphy. J Nucl Med 32 (1991) 1782
44. Hommeyer S.H., Varney D.M., and Eary J.F. Skeletal non-visualization in a bone scan secondary to intravenous etidronate therapy. J Nucl Med 33 (1992) 748
45. Kayano H., Schimizu T., and Shishiba Y. The bisphosphonate dilemma. J Nucl Med 36 (1995) 705
46. Caraglia M., Santini D., Marra M., et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13 (2006) 7
47. Woo S.B., and Solomon D.H. Bisphosphonate therapy for cancer and prevalence of inflammatory jaw conditions. J Nat Cancer Inst 99 (2007) 986